- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Austin Frakt on the Importance of Patients Making Informed Care Decisions
When patients overestimate the benefits of intervention and underestimate the harms of treatments, they may not be receiving the right forms of care that they should be, said Austin Frakt, PhD, health economist and researcher.
When patients overestimate the benefits of intervention and underestimate the harms of treatments, they may not be receiving the right forms of care that they should be, said Austin Frakt, PhD, health economist and researcher.
He adds that its critically important that patients make informed decisions so that he or she can then add or drop care as needed.
“This isn’t really necessarily about reducing care or reducing health spending, although that could happen,” Dr Frakt explains. “It’s more about making informed choices so that the care that’s delivered is of greatest value to the patient based on what they think is right for them.”
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
